Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis.
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Koichi
K
Yanaba
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Yoshinori
Y
Umezawa
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Reiko
R
Sakakihara
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Miki
M
Chiba
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Toshihiro
T
Ito
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Sota
S
Kikuchi
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Osamu
O
Fukuchi
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Akihiko
A
Asahina
Department of Dermatology, Nippon Medical School, Tokyo, Japan.
Hidehisa
H
Saeki
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Hidemi
H
Nakagawa
D000068879:Adalimumab; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab